FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3211550552> ?p ?o ?g. }

• W3211550552 endingPage "916" @default.
• W3211550552 startingPage "916" @default.
• W3211550552 abstract "Abstract INTRODUCTION Vaso-occlusive crisis (VOC), hallmark of sickle-cell disease (SCD), is the first cause of patients' emergency room (ER) admissions and hospitalizations. Acute chest syndrome (ACS) is a life-threatening complication that can occur during VOC and prolong hospitalization and is one of the main causes of death in SCD patients. The PRESEV score, established by team members and colleagues, assesses the risk of developing ACS (Bartolucci et al., 2016). In addition, the score has been validated by an international multicenter study, involving 13 centers, distributed in five different countries (PRESEV 2 - ASH 2020). Throughout the first wave of the Covid-19 pandemic, VOC management for SCD patients was a major concern. Our sickle cell referral center set up a hotline to monitor patients suffering from VOC daily, and organized the deployment of home-care services when required. The success of this system during the first wave of the pandemic led to the establishment of DREPADOM, a home-care and hospitalization protocol for VOC management in patients who are at a low risk of developing ACS, as standard care. DESCRIPTION OF SETTING Patients eligible for DREPADOM are patients that arrive at the ER for a VOC with a low PRESEV score, meaning low risk of developing ACS; or patients that are discharged early following hospitalization for VOC. After physical examination and calculation of the PRESEV score, DREPADOM home hospitalization is systematically offered to patients arriving to the ER with a PRESEV score ≤ 5. If the patient agrees, the DREPADOM nurse coordinator then acts as a link between the pharmacist, the oxygen supplier, the homecare provider, and the DREPADOM medical platform to activate the home hospitalization protocol. This entails the delivery of oxygen supply at the patient's house, dispatch of a medical prescription of opioids and parenteral treatments, twice/thrice-daily visits from homecare nurses, and an on-call SCD expert. DREPADOM relies on a system of daily telephone calls with three levels of expertise and warning and a decision-making algorithm. This is supervised by SCD experts, who arbitrate according to the evolution of the situation (stopping the follow-up, continuing the follow-up as an outpatient, hospitalization) (Fig.1). Furthermore, nurses enter patient vitals in real-time during their daily visits on a dedicated online platform (Link4Life) that contains an integrated automatic alert system. Additionally, a daily phone update between the DREPADOM coordination and the homecare provider's coordination concerning status and evolution of the patient's global condition takes place. RESULTS Over a 6-month period, 39 patients were included in the DREPADOM home hospitalization protocol, 3 of which were included multiple times for a total of 42 inclusions. Mean age was 40 years old [±9], sex ratio was 14/25 (male/female), ER vs early discharge ratio was 21/22, and mean homecare follow-up was 3 days (±1) for both, patients arriving from the ER and early discharge patients. Throughout the third wave of the pandemic, when hospital saturation was a major concern, patients with PRESEV scores 5 ≤ 11 were also offered DREPADOM. Three patients were hospitalized (7%): one for an ACS, who was included during the 3 rd wave of the pandemic with a PRESEV score of 8; one for pyelonephritis unrelated to the VOC; and one for difficulties with venous access. No death was reported. PERSPECTIVES Preliminary satisfaction surveys show a great enthusiasm for DREPADOM, partly due to the high standard of care received, but also due to the shorter length of hospitalization. In fact, median hospital stay for VOC is 4 [3-7] days (Bartolucci, 2016) whereas median homecare follow-up was 3 [1-6] days. Figure 1 Figure 1. Disclosures Bartolucci: Hemanext: Consultancy; Jazz Pharma: Other: Lecture fees; AGIOS: Consultancy; F. Hoffmann-La Roche Ltd: Consultancy; Emmaus: Consultancy; GBT: Consultancy; INNOVHEM: Other: Co-founder; Bluebird: Consultancy, Research Funding; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Other: Lecture fees, Steering committee, Research Funding; Addmedica: Consultancy, Other: Lecture fees, Research Funding; Fabre Foundation: Research Funding." @default.
• W3211550552 created "2021-11-22" @default.
• W3211550552 creator A5000237074 @default.
• W3211550552 creator A5004706934 @default.
• W3211550552 creator A5005510937 @default.
• W3211550552 creator A5008363475 @default.
• W3211550552 creator A5010264572 @default.
• W3211550552 creator A5023898438 @default.
• W3211550552 creator A5025594383 @default.
• W3211550552 creator A5031884367 @default.
• W3211550552 creator A5033564917 @default.
• W3211550552 creator A5041135230 @default.
• W3211550552 creator A5041859157 @default.
• W3211550552 creator A5048418903 @default.
• W3211550552 creator A5068166243 @default.
• W3211550552 creator A5070765520 @default.
• W3211550552 creator A5072904906 @default.
• W3211550552 creator A5087175279 @default.
• W3211550552 date "2021-11-05" @default.
• W3211550552 modified "2023-10-05" @default.
• W3211550552 title "Drepadom - Establishment of Home Care Services and Hospitalizations for Sickle Cell Disease Patients As Standard Care Since the Covid-19 Pandemic" @default.
• W3211550552 doi "https://doi.org/10.1182/blood-2021-147740" @default.
• W3211550552 hasPublicationYear "2021" @default.
• W3211550552 type Work @default.
• W3211550552 sameAs 3211550552 @default.
• W3211550552 citedByCount "0" @default.
• W3211550552 crossrefType "journal-article" @default.
• W3211550552 hasAuthorship W3211550552A5000237074 @default.
• W3211550552 hasAuthorship W3211550552A5004706934 @default.
• W3211550552 hasAuthorship W3211550552A5005510937 @default.
• W3211550552 hasAuthorship W3211550552A5008363475 @default.
• W3211550552 hasAuthorship W3211550552A5010264572 @default.
• W3211550552 hasAuthorship W3211550552A5023898438 @default.
• W3211550552 hasAuthorship W3211550552A5025594383 @default.
• W3211550552 hasAuthorship W3211550552A5031884367 @default.
• W3211550552 hasAuthorship W3211550552A5033564917 @default.
• W3211550552 hasAuthorship W3211550552A5041135230 @default.
• W3211550552 hasAuthorship W3211550552A5041859157 @default.
• W3211550552 hasAuthorship W3211550552A5048418903 @default.
• W3211550552 hasAuthorship W3211550552A5068166243 @default.
• W3211550552 hasAuthorship W3211550552A5070765520 @default.
• W3211550552 hasAuthorship W3211550552A5072904906 @default.
• W3211550552 hasAuthorship W3211550552A5087175279 @default.
• W3211550552 hasBestOaLocation W32115505521 @default.
• W3211550552 hasConcept C126322002 @default.
• W3211550552 hasConcept C141668000 @default.
• W3211550552 hasConcept C177713679 @default.
• W3211550552 hasConcept C187212893 @default.
• W3211550552 hasConcept C194828623 @default.
• W3211550552 hasConcept C2776135927 @default.
• W3211550552 hasConcept C2778620579 @default.
• W3211550552 hasConcept C2779134260 @default.
• W3211550552 hasConcept C2780976302 @default.
• W3211550552 hasConcept C3008058167 @default.
• W3211550552 hasConcept C41008148 @default.
• W3211550552 hasConcept C512399662 @default.
• W3211550552 hasConcept C524204448 @default.
• W3211550552 hasConcept C545542383 @default.
• W3211550552 hasConcept C71924100 @default.
• W3211550552 hasConcept C76155785 @default.
• W3211550552 hasConcept C89623803 @default.
• W3211550552 hasConceptScore W3211550552C126322002 @default.
• W3211550552 hasConceptScore W3211550552C141668000 @default.
• W3211550552 hasConceptScore W3211550552C177713679 @default.
• W3211550552 hasConceptScore W3211550552C187212893 @default.
• W3211550552 hasConceptScore W3211550552C194828623 @default.
• W3211550552 hasConceptScore W3211550552C2776135927 @default.
• W3211550552 hasConceptScore W3211550552C2778620579 @default.
• W3211550552 hasConceptScore W3211550552C2779134260 @default.
• W3211550552 hasConceptScore W3211550552C2780976302 @default.
• W3211550552 hasConceptScore W3211550552C3008058167 @default.
• W3211550552 hasConceptScore W3211550552C41008148 @default.
• W3211550552 hasConceptScore W3211550552C512399662 @default.
• W3211550552 hasConceptScore W3211550552C524204448 @default.
• W3211550552 hasConceptScore W3211550552C545542383 @default.
• W3211550552 hasConceptScore W3211550552C71924100 @default.
• W3211550552 hasConceptScore W3211550552C76155785 @default.
• W3211550552 hasConceptScore W3211550552C89623803 @default.
• W3211550552 hasIssue "Supplement 1" @default.
• W3211550552 hasLocation W32115505521 @default.
• W3211550552 hasLocation W32115505522 @default.
• W3211550552 hasOpenAccess W3211550552 @default.
• W3211550552 hasPrimaryLocation W32115505521 @default.
• W3211550552 hasRelatedWork W155955336 @default.
• W3211550552 hasRelatedWork W1965738657 @default.
• W3211550552 hasRelatedWork W1987738542 @default.
• W3211550552 hasRelatedWork W2099191183 @default.
• W3211550552 hasRelatedWork W2159824171 @default.
• W3211550552 hasRelatedWork W2216819536 @default.
• W3211550552 hasRelatedWork W2334263927 @default.
• W3211550552 hasRelatedWork W242090125 @default.
• W3211550552 hasRelatedWork W2467879455 @default.
• W3211550552 hasRelatedWork W2966715040 @default.
• W3211550552 hasVolume "138" @default.
• W3211550552 isParatext "false" @default.
• W3211550552 isRetracted "false" @default.
• W3211550552 magId "3211550552" @default.
• W3211550552 workType "article" @default.